Patents by Inventor Herman Waldmann
Herman Waldmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124551Abstract: Provided herein is a synthetic complex comprising one or more human leukocyte antigens (synHLA), wherein said complex is inhibited from eliciting an immune response. Also provided are a nucleic acid molecule encoding said complex, an immune incompetent stem cell comprising said complex or said nucleic acid molecule, and a method of treating a disease or disorder comprising administering said complex, said nucleic acid molecule, or said immune incompetent stem cell to a subject in need thereof.Type: ApplicationFiled: April 19, 2023Publication date: April 18, 2024Inventors: Herman WALDMANN, Ashley BUCKLE, Adrian WOOLFSON
-
Publication number: 20210269544Abstract: A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.Type: ApplicationFiled: October 12, 2020Publication date: September 2, 2021Inventors: Herman WALDMANN, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Ricardo Simoes Da Silva Graca
-
Patent number: 10906976Abstract: The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance.Type: GrantFiled: November 23, 2016Date of Patent: February 2, 2021Assignee: The Chinese University of Hong KongInventors: Oi Lan Kathy Lui, Herman Waldmann
-
Patent number: 10800850Abstract: A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.Type: GrantFiled: December 18, 2015Date of Patent: October 13, 2020Assignee: CytomX Therapeutics, Inc.Inventors: Herman Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Richardo Simoes Da Silva Graca
-
Publication number: 20170151327Abstract: The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance.Type: ApplicationFiled: November 23, 2016Publication date: June 1, 2017Inventors: OI LAN KATHY LUI, Herman Waldmann
-
Publication number: 20170137529Abstract: A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.Type: ApplicationFiled: December 18, 2015Publication date: May 18, 2017Inventors: Herman Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Richardo Simoes Da Silva Graca
-
Patent number: 8921104Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: GrantFiled: June 29, 2012Date of Patent: December 30, 2014Assignee: ISIS Innovation LimitedInventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
-
Publication number: 20140212418Abstract: A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.Type: ApplicationFiled: July 31, 2013Publication date: July 31, 2014Inventors: Herman Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Richardo Simoes Da Silva Graca
-
Publication number: 20130171627Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: ApplicationFiled: June 29, 2012Publication date: July 4, 2013Inventors: Herman WALDMANN, Paul J. FAIRCHILD, Richard GARDNER, Frances BROOK
-
Patent number: 8440190Abstract: This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.Type: GrantFiled: July 14, 2005Date of Patent: May 14, 2013Assignee: Isis Innovation LimitedInventors: Herman Waldmann, Lisa K Gilliland, Masahide Tone, Mark R Frewin, Louise Walsh
-
Publication number: 20130028893Abstract: A therapeutic protein, such as a therapeutic antibody, that is modified with a compound that inhibits binding of the protein to its therapeutic target, thereby reducing side effects caused by the protein.Type: ApplicationFiled: August 19, 2011Publication date: January 31, 2013Inventors: Herman Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Ricardo Simoes DaSilva Graca
-
Publication number: 20120282184Abstract: A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to treat these conditions, diagnosing or predicting these conditions and selecting and monitoring therapies.Type: ApplicationFiled: October 29, 2010Publication date: November 8, 2012Applicant: ISIS INNOVATION LTDInventors: Herman Waldmann, Kathleen Nolan, Lynn Poulton
-
Patent number: 8232100Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: GrantFiled: July 21, 2010Date of Patent: July 31, 2012Assignee: Isis Innovation LimitedInventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
-
Publication number: 20110282037Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: ApplicationFiled: June 17, 2011Publication date: November 17, 2011Inventors: Herman WALDMANN, Mark Frewin
-
Patent number: 7993641Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: October 16, 2006Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7994289Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: June 18, 2003Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7947272Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.Type: GrantFiled: July 13, 2006Date of Patent: May 24, 2011Assignees: Tolerx, Inc., Isis Innovation, Ltd., Cambridge University Technical Services, Ltd.Inventors: Mark Frewin, Herman Waldmann, Scott Gorman, Geoff Hale, Patricia Rao, Tadeusz Kornaga, Douglas Ringler, Stephen Cobbold, Dawn Winsor-Hines
-
Publication number: 20110014696Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: ApplicationFiled: July 21, 2010Publication date: January 20, 2011Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
-
Patent number: RE43898Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: September 16, 1991Date of Patent: January 1, 2013Assignee: Glaxo Wellcome Inc. ResearchInventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
-
Patent number: RE46877Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: November 21, 2012Date of Patent: May 29, 2018Assignee: BTG INTERNATIONAL LIMITEDInventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann